ArticleClinical oral investigations2026
20-year experience of biomet stock alloplastic temporomandibular joint replacement in Chinese patients after technical modifications: a single-center retrospective study.
Article in Clinical oral investigations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesTo evaluate the clinical and radiographic outcomes of the Biomet stock alloplastic temporomandibular joint replacement (ATJR) after seven progressive surgical modifications in Chinese patients at a single center. MATERIALS AND
methodsPatients who underwent ATJR from 2005 to 2025 were retrospectively reviewed. Seven surgical modifications were progressively introduced to optimize outcomes. Maximum interincisal opening (MIO), visual analogue scale (VAS) for pain, dietary function and mandibular mobility, and quality of life (QoL) were compared between baseline and final follow-up of at least 12 months. Postoperative computed tomography (CT) was used to evaluate prosthesis stability, screw position and heterotopic ossification (HO). Complications, revision rates, and Kaplan-Meier prosthesis survival rate were analyzed.
results300 patients with 392 prostheses were included in the study. After a mean follow-up of 67.4±43.5 (12-208) months, MIO improved significantly from 23.7±13.5 mm to 34.2±6.9 mm (p < 0.001). QoL improved by 36.6% and VAS scores improved by 63.8-76.3%. 222 patients with 289 prostheses had CT follow-up exams 12-183 months after surgery (mean 40.9±33.7). HO of varying degrees was observed in 116 prostheses (40.1%) and screw loosening occurred in 7 prostheses (2.4%). 12 prostheses were revised (3.1%) including infection, persistent discomfort, screw loosening or severe HO. Cumulative prosthesis survival rates were 99.1%, 98.1%, 96.9%, and 94.7% at 1, 3, 5 and 10 years, respectively.
conclusionsBiomet stock ATJR has satisfactory results in Chinese patients with surgical modifications. CLINICAL RELEVANCE: Long-term follow-up of Biomet stock ATJR in Chinese patients showed satisfactory clinical, radiological and survival rates with surgical modifications, supporting its broader application in populations with anatomical features distinct from those of Western patients.
Indexed as
Identifiers
42687076What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.